Analyst David Saxon of Needham maintained a Buy rating on RxSight (RXST – Research Report), reducing the price target to $22.00.
David Saxon’s rating is based on RxSight’s promising market position and growth potential. The company has shown resilience in navigating market challenges, including tariffs and economic dynamics, which positions it well for future success. Saxon also considered the revised 2025 guidance, which reflects a strategic approach to capturing market opportunities and improving financial performance.
Additionally, RxSight’s innovative product offerings and strategic initiatives are expected to drive revenue growth and enhance shareholder value. Despite a lowered price target, the overall outlook remains positive, supporting the Buy recommendation. Saxon believes that the company’s strengths and strategic direction justify a favorable investment outlook.
Saxon covers the Healthcare sector, focusing on stocks such as RxSight, DENTSPLY SIRONA, and Globus Medical. According to TipRanks, Saxon has an average return of -4.2% and a 29.49% success rate on recommended stocks.
In another report released on April 3, Morgan Stanley also maintained a Buy rating on the stock with a $42.00 price target.